What is HC Wainwright’s Forecast for RMTI Q1 Earnings?

Rockwell Medical, Inc. (NASDAQ:RMTI) – Equities researchers at HC Wainwright issued their Q1 2027 earnings estimates for Rockwell Medical in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju forecasts that the company will post earnings per share of ($0.01) for the quarter. HC Wainwright currently has a “Buy” rating and a $2.00 price target on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Rockwell Medical’s Q2 2027 earnings at $0.01 EPS, Q3 2027 earnings at $0.01 EPS, Q4 2027 earnings at $0.02 EPS and FY2027 earnings at $0.04 EPS.

Rockwell Medical (NASDAQ:RMTI) last released its earnings results on Thursday, March 26th. The company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). The firm had revenue of $18.35 million during the quarter, compared to analyst estimates of $18.58 million. Rockwell Medical had a negative return on equity of 15.64% and a negative net margin of 7.67%.

Several other brokerages have also recently weighed in on RMTI. Wall Street Zen raised Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Rockwell Medical in a report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $2.00.

Rockwell Medical Stock Up 4.5%

RMTI opened at $0.93 on Tuesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.63 and a current ratio of 3.98. The company has a market capitalization of $36.77 million, a PE ratio of -6.22 and a beta of 1.70. The stock’s fifty day moving average is $1.00 and its 200-day moving average is $1.03. Rockwell Medical has a one year low of $0.78 and a one year high of $2.10.

Institutional Investors Weigh In On Rockwell Medical

Several hedge funds have recently modified their holdings of RMTI. Panagora Asset Management Inc. acquired a new position in shares of Rockwell Medical in the 2nd quarter valued at $41,000. XTX Topco Ltd raised its holdings in Rockwell Medical by 286.5% during the 4th quarter. XTX Topco Ltd now owns 62,097 shares of the company’s stock worth $52,000 after buying an additional 46,029 shares during the period. Jane Street Group LLC acquired a new stake in Rockwell Medical during the 4th quarter worth about $84,000. GSA Capital Partners LLP lifted its stake in Rockwell Medical by 635.1% during the third quarter. GSA Capital Partners LLP now owns 163,978 shares of the company’s stock valued at $197,000 after buying an additional 141,672 shares in the last quarter. Finally, Geode Capital Management LLC lifted its stake in Rockwell Medical by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 364,816 shares of the company’s stock valued at $304,000 after buying an additional 41,668 shares in the last quarter. 23.31% of the stock is owned by hedge funds and other institutional investors.

Rockwell Medical Company Profile

Rockwell Medical, Inc is a Delaware‐domiciled biopharmaceutical company focused on the development and commercialization of therapies for patients with chronic kidney disease (CKD). The company’s mission centers on addressing common complications in CKD—namely iron deficiency and secondary hyperparathyroidism—through innovative treatment approaches designed for dialysis settings.

The company’s lead product, TRIFERIC®, is an iron replacement therapy approved by the U.S. Food and Drug Administration for use in hemodialysis patients.